AIRLINK 189.36 Increased By ▲ 1.33 (0.71%)
BOP 11.10 Decreased By ▼ -0.76 (-6.41%)
CNERGY 7.28 Decreased By ▼ -0.26 (-3.45%)
FCCL 36.65 Decreased By ▼ -1.14 (-3.02%)
FFL 14.95 Decreased By ▼ -0.29 (-1.9%)
FLYNG 26.19 Increased By ▲ 0.66 (2.59%)
HUBC 130.89 Increased By ▲ 0.74 (0.57%)
HUMNL 13.47 Decreased By ▼ -0.14 (-1.03%)
KEL 4.28 Decreased By ▼ -0.07 (-1.61%)
KOSM 6.08 Decreased By ▼ -0.09 (-1.46%)
MLCF 45.94 Increased By ▲ 0.26 (0.57%)
OGDC 201.86 Decreased By ▼ -4.57 (-2.21%)
PACE 6.12 Decreased By ▼ -0.26 (-4.08%)
PAEL 38.36 Decreased By ▼ -1.95 (-4.84%)
PIAHCLA 16.73 Decreased By ▼ -0.22 (-1.3%)
PIBTL 7.94 Decreased By ▼ -0.09 (-1.12%)
POWER 9.86 Decreased By ▼ -0.17 (-1.69%)
PPL 173.46 Decreased By ▼ -5.38 (-3.01%)
PRL 34.73 Decreased By ▼ -1.63 (-4.48%)
PTC 23.95 Decreased By ▼ -0.44 (-1.8%)
SEARL 101.74 Decreased By ▼ -1.42 (-1.38%)
SILK 1.07 No Change ▼ 0.00 (0%)
SSGC 32.70 Decreased By ▼ -3.54 (-9.77%)
SYM 17.93 Decreased By ▼ -0.30 (-1.65%)
TELE 8.14 Decreased By ▼ -0.24 (-2.86%)
TPLP 12.02 Decreased By ▼ -0.14 (-1.15%)
TRG 67.40 Increased By ▲ 0.07 (0.1%)
WAVESAPP 11.80 Decreased By ▼ -0.21 (-1.75%)
WTL 1.52 Decreased By ▼ -0.05 (-3.18%)
YOUW 3.90 Increased By ▲ 0.01 (0.26%)
BR100 11,819 Decreased By -87.9 (-0.74%)
BR30 35,000 Decreased By -554.1 (-1.56%)
KSE100 112,085 Decreased By -478.8 (-0.43%)
KSE30 34,946 Decreased By -148 (-0.42%)

ISLAMABAD: The Competition Commission of Pakistan (CCP) Friday approved the acquisition of trademarks for the pharmaceutical product Claforan by Hoechst Pakistan Limited from Sanofi Aventis Deutschland GMBH through a Trademark Assignment Agreement.

Hoechst Pakistan Limited, a public listed company in Pakistan, specializes in the manufacture, sale, and trading of pharmaceutical products. Sanofi Aventis Deutschland GMBH, a German-based limited liability company, is a prominent pharmaceutical manufacturer and distributor across Europe. With this transaction, Sanofi is transferring Claforan’s trademarks to Hoechst, positioning Hoechst as a key player in Pakistan’s pharmaceutical industry.

CCP’s assessment identified the relevant market as “Systemic Antibiotics” and classified the transaction as a horizontal merger. Hoechst Pakistan’s market share will remain stable, as it has already been producing Claforan under license from Sanofi Aventis. This acquisition, therefore, will not alter the market balance but will strategically enhance Hoechst’s position.

The CCP concluded that the acquisition would not lead to market dominance and authorized the transaction under Section 31(1)(d)(i) of the Competition Act.

The relevant product market, in this case has been identified as “Systemic Antibiotics” (Claforan) while the relevant geographic market is “Pakistan”.

The Acquirer and Seller are both active in the same therapeutic class with a different brand name making it a horizontal merger. The total estimated market share of the Acquirer is 1.12 percent which will remain unchanged post-transaction as the Acquirer is currently manufacturing the product under the license from the Seller.

The proposed transaction will not result in dominance of the Acquirer in the relevant market, post-transaction, as determined under Section 2(1)(e) read with Section 3 of the Act. Therefore, the said transaction is hereby authorized under Section 31(1)(d)(i) of the Act.

Copyright Business Recorder, 2024

Comments

Comments are closed.